No Data
No Data
10-Q: Quarterly report
Express News | News On Avista Public Acquisition Corp. II (AHPA,OABIV) Now Under OABI
OmniAb Announces Completion of Spin-Off and Business Combination
Ligand Announces That Janssen Has Received Approval From U.S FDA For Tecvayli For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma; Under The Terms OmniAb Is Eligible To Receive A $25M Milestone Payment Upon The First Commercial Sale
First FDA approval of a bispecific antibody discovered using OmniAb technologyOmniAb, Inc. is eligible to receive a $25 million milestone upon first commercial sale in the United StatesLigand Pharmace
SPAC APAC Shareholders Approve Merger With Ligand Spinoff OmniAb
Avista Public Acquisition Corp. II And OmniAb Business Combination Approved By APAC Shareholders Closing Scheduled for November 1;
APAC Shareholder Approval Obtained, Closing Scheduled for November 1, 2022Ligand "Regular Way" and "Ex-Distribution" and OmniAb "When-Issued" Set to Begin Trading on October 25, 2022Ligand Pharmaceuti
No Data
Anonymous Investor : Dude. Volume is ABSOLUTELY DEAD not worth it unless shorts are involved